-+ 0.00%
-+ 0.00%
-+ 0.00%

Bicycle Therapeutics presents interim Duravelo-2 BT8009 plus Keytruda data at ASCO 2026

PUBT·04/21/2026 14:31:28
Listen to the news
Bicycle Therapeutics presents interim Duravelo-2 BT8009 plus Keytruda data at ASCO 2026
  • Bicycle Therapeutics scheduled interim results from Duravelo-2 studies of zelenectide pevedotin (BT8009), including a pembrolizumab combination in first-line locally advanced or metastatic urothelial carcinoma, for presentation at ASCO 2026.
  • Rapid oral presentation is set for June 1, covering previously untreated patients with locally advanced or metastatic urothelial carcinoma.
  • Multiple posters on May 31 will provide updated findings from Duravelo-1 monotherapy and combination cohorts, focusing on previously treated metastatic urothelial carcinoma and cisplatin-ineligible first-line patients.
  • Additional ASCO poster will outline quantitative work intended to support selection of an optimized BT8009 dose in locally advanced or metastatic urothelial carcinoma.
  • Company plans to post presentation materials on its website on mornings of each session.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicycle Therapeutics plc published the original content used to generate this news brief via Business Wire (Ref. ID: 202604211031BIZWIRE_USPR_____20260420_BW659430) on April 21, 2026, and is solely responsible for the information contained therein.